InvestorsHub Logo
Followers 14
Posts 2778
Boards Moderated 0
Alias Born 12/23/2014

Re: Topgun54 post# 450

Wednesday, 03/08/2023 5:23:36 PM

Wednesday, March 08, 2023 5:23:36 PM

Post# of 459
Is it smelling better now?

.KORU Medical Systems Announces 2022 Q4 and Full Year Financial Results, Accelerating to 19% Revenue Growth in 2022

Recent Highlights:

Fourth quarter net revenue growth of 13% to $7.3 million, marking the fifth consecutive quarter of double-digit growth, and full year net revenue growth of 19% to $27.9 million

Novel Therapies business finished the year with 14 total collaborations to date – growing pre-commercial revenue from $0.5 million in 2021 to $2.5 million for full year 2022

11% Core business growth (U.S. and International) for the year driven by overall SCIg market growth and market share gains through prefilled syringe adoptions

Improved cash position to $17.4 million ending the fourth quarter via strong working capital management

2023 net revenues expected to be between $32.5 and $33.5 million, representing growth in the range of 17-20%
Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KRMD News